- Home
- FRD vs NTHI Comparison
FRD vs NTHI Comparison
Compare FRD & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- NTHI
- Stock Information
- Founded
- FRD 1965
- NTHI 2008
- Country
- FRD United States
- NTHI United States
- Employees
- FRD N/A
- NTHI N/A
- Industry
- FRD Steel/Iron Ore
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- NTHI Health Care
- Exchange
- FRD Nasdaq
- NTHI Nasdaq
- Market Cap
- FRD 114.4M
- NTHI 111.5M
- IPO Year
- FRD N/A
- NTHI N/A
- Fundamental
- Price
- FRD $17.53
- NTHI $5.85
- Analyst Decision
- FRD
- NTHI
- Analyst Count
- FRD 0
- NTHI 0
- Target Price
- FRD N/A
- NTHI N/A
- AVG Volume (30 Days)
- FRD 26.2K
- NTHI 320.0K
- Earning Date
- FRD 08-07-2025
- NTHI 08-19-2025
- Dividend Yield
- FRD 0.91%
- NTHI N/A
- EPS Growth
- FRD N/A
- NTHI N/A
- EPS
- FRD 1.21
- NTHI N/A
- Revenue
- FRD $464,826,000.00
- NTHI $59,990.00
- Revenue This Year
- FRD N/A
- NTHI N/A
- Revenue Next Year
- FRD N/A
- NTHI N/A
- P/E Ratio
- FRD $14.47
- NTHI N/A
- Revenue Growth
- FRD N/A
- NTHI N/A
- 52 Week Low
- FRD $12.24
- NTHI $3.20
- 52 Week High
- FRD $18.48
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- FRD 61.48
- NTHI N/A
- Support Level
- FRD $16.46
- NTHI N/A
- Resistance Level
- FRD $17.63
- NTHI N/A
- Average True Range (ATR)
- FRD 0.68
- NTHI 0.00
- MACD
- FRD 0.14
- NTHI 0.00
- Stochastic Oscillator
- FRD 89.88
- NTHI 0.00
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").